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In breast cancer there are clearly a number of factors that
counter-intuitively influence outcome or for which there is a
change, after a considerable time, in longstanding evidence
that outcome was not affected. The latter is well represented
by the effect of postoperative radiotherapy in early breast
cancer on overall survival. There was clear evidence that such
treatment reduced local recurrence risk (by about two-thirds)
and risk of death from breast cancer (by one-sixth [1]), but
until 1997 evidence suggested treatment would not improve
overall survival. The results in that year of two randomised
trials in high-risk patients showed that the addition of
postmastectomy radiotherapy to adjuvant chemotherapy
improved overall survival [2,3].
Ragaz argues from the updated results of these pivotal
Canadian and Danish trails, from survival trends observed in
British Columbia, Canada and from the data presented
consistently from 1990 to 2005 by the Early Breast Cancer
Trialists’ Collaborative Group that this effect on outcome is
real [4]. The reality is explained by the record reduction over
this period in post-radiotherapy acute and late morbidity due
to improved techniques and dosimetry.
Ragaz also indicates that, due to lack of radiotherapy trials,
there is no clarity on what needs to be irradiated, while the
question of who needs to be irradiated can no longer be
answered simplistically on the basis of the number of nodes
involved. The histopathological extent of nodal involvement
judged by the percentage of involved nodes, by the spread
within a node and by the presence of extracapsular spread –
all indicators of risk of systemic relapse – is more critical than
the indicators of increased risk of local failure.
The need for more trials in radiotherapy is underlined by the
fact that this paradigm shift in attitude and assessment of
benefit occurred when the results of the pivotal randomised
trials were published in 1997 showing that postoperative
radiotherapy could improve long-term overall survival and not
just cause long-term morbidity.
That a single measurement of Ki67 does predict long-term
outcome is discussed by Dowsett and colleagues [5], but
with the caveat that such a single assay may not deliver all of
the required information. For prognosis alone, a single
pretreatment assay suffices – but for predictive information, a
second post-treatment assay in the neoadjuvant case is
needed. Further assays offer even more information for drug
development studies or of drug resistance mechanisms.
While breast stroma has been of passing interest to
pathologists since at least the 1960s, when elastosis was
considered a possible marker of prognosis, the hypothesis
that malignant epithelial cells alone are prognostic and the
supporting (stromal) tissues are of no prognostic influence
has generally been the focus of research and clinical interest.
This no longer stands up to scrutiny. Howell and colleagues
describe well how stroma is recruited by tumours, is variable
from tumour to tumour, and how tumour genes may be
downregulated (for adhesion) or upregulated (facilitating cell
movement) [6] – all potentially affecting outcome. Stroma
does not, however, integrate with other prognostic factors.
Stroma is already targeted in various ways in clinical situations.
Bevacizumab and the bisphosphonates are already in regular
and effective use. There is, therefore, opportunity for further
improvement in outcomes as other stromal targets are explored.
‘Who would have thought it!’ is a statement and not a
question. Many did think it, and that is why the critically
important trials in postmastectomy radiotherapy were carried
out even though some trialists expected the old paradigm to
be confirmed. Newer technologies now enable pathologists
and clinicians to revisit hypotheses on stroma mooted
40 years ago. Neoadjuvant treatments also facilitate assess-
ment of the prognostic effects of molecular and genetic
factors. Clearly, it is having the thought that counts.
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